Arcellx, Inc. is a clinical-stage biotechnology company developing immunotherapies for cancer and other incurable diseases. Its proprietary D-Domain synthetic binding scaffold powers two therapeutic platforms: ddCARs (classical single-infusion CAR-Ts) and ARC-SparX (dosable, controllable universal CAR-Ts). Its lead product, anito-cel (anitocabtagene autoleucel), targets BCMA in relapsed/refractory multiple myeloma and has a BLA submitted to the FDA. The company also has programs in AML, MDS, and autoimmune diseases such as generalized Myasthenia Gravis.
Q2 FY2026 — expected 2026-08-07
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001193125-26-076876 | EDGAR | 116K words |
| 2025-02-27 | 2024-12-31 | 0000950170-25-029150 | EDGAR | 110K words |
| 2024-02-28 | 2023-12-31 | 0000950170-24-022048 | EDGAR | 110K words |
| 2023-03-29 | 2022-12-31 | 0000950170-23-010610 | EDGAR | 107K words |
| 2022-03-24 | 2021-12-31 | 0000950170-22-004573 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001193125-25-266932 | EDGAR | 63K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105064 | EDGAR | 62K words |
| 2025-05-08 | 2025-03-31 | 0000950170-25-067100 | EDGAR | 60K words |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123442 | EDGAR | 63K words |
| 2024-08-08 | 2024-06-30 | 0000950170-24-094120 | EDGAR | 62K words |
| 2024-05-09 | 2024-03-31 | 0000950170-24-057007 | EDGAR | 60K words |
| 2023-11-13 | 2023-09-30 | 0000950170-23-062930 | EDGAR | 77K words |
| 2023-08-14 | 2023-06-30 | 0000950170-23-042402 | EDGAR | 76K words |
| 2023-05-08 | 2023-03-31 | 0000950170-23-018782 | EDGAR | 72K words |
| 2022-11-14 | 2022-09-30 | 0000950170-22-025099 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0000950170-22-017455 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0000950170-22-009732 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-23 | 0001193125-26-063955 | EDGAR | 52K words |
| 2025-12-08 | 0001193125-25-311276 | EDGAR | 2K words |
| 2025-11-05 | 0001193125-25-266866 | EDGAR | 1K words |
| 2025-08-07 | 0000950170-25-105015 | EDGAR | 1K words |
| 2025-05-28 | 0001193125-25-129522 | EDGAR | 1K words |
| 2025-05-14 | 0001193125-25-119506 | EDGAR | 1K words |
| 2025-05-08 | 0001193125-25-116023 | EDGAR | 2K words |
| 2025-03-20 | 0001193125-25-058978 | EDGAR | 1K words |
| 2025-02-27 | 0001193125-25-039316 | EDGAR | 2K words |
| 2024-12-12 | 0001193125-24-275844 | EDGAR | 6K words |
73 total filings indexed. 46 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001786205 |
| Ticker | ACLX |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ACLX (~200 tokens, structured JSON with cryptographic provenance)